Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Código QR

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Guardado en:

Detalles Bibliográficos
Autores principales:	C. I. Edvard Smith, Jennifer R. Brown, Rula Zain
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	BTK ibrutinib inhibitors leukemia lymphoma Waldenström’s macroglobulinemia Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/79deb5036c8b4031833663ec890f7e65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo J, et al.
Publicado: (2016)

Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile
por: Cardemil,Daniela, et al.
Publicado: (2019)

Diagnostic Criteria for Macular Edema Associated with Venous Occlusions
por: A. G. Shchuko, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Leigh Naylor-Adamson, et al.
Publicado: (2021)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: Susan M. O’Brien, et al.
Publicado: (2021)

The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
por: Kamil D. Kaplanov
Publicado: (2021)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
por: Ridhima Kapoor, MD, et al.
Publicado: (2021)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
por: Seegobin K, et al.
Publicado: (2021)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan BK, et al.
Publicado: (2021)

Leukemia & lymphoma
Publicado: (1989)

Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
por: Lukas M. Braun, et al.
Publicado: (2021)

Lymphoma & Chronic Lymphocytic Leukemias

Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
por: Andrei A. Petrenko, et al.
Publicado: (2021)

Ocurrencia de leucemia mieloide crónica y linfoma no Hodgkin en un mismo paciente: Caso clínico
por: Morales F,Eugenia, et al.
Publicado: (1999)

Adult T-cell leukemia/lymphoma: a case report of primary cutaneous tumoral type
por: Julia Ocampo Lyra-da Sylva, et al.
Publicado: (2012)

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
por: Holger Scheible, et al.
Publicado: (2021)

Síndromes linfoproliferativos crónicos en Chile: Estudio prospectivo de 132 casos
por: Cabrera C,María Elena, et al.
Publicado: (2003)

Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia
por: Ramos Peñafiel,Christian, et al.
Publicado: (2018)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Federica Frezzato, et al.
Publicado: (2021)

Leucemia linfoma T del adulto en Chile.: Estudio clínico-patológico y molecular de 26 pacientes
por: Cabrera C,M Elena, et al.
Publicado: (1999)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat YF, et al.
Publicado: (2016)

Ajuste de intensidad para el trasplante hematopoyético alogénico en leucemia aguda
por: Sarmiento M,Mauricio, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells
por: Seo,Hyang‑Hee, et al.
Publicado: (2017)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Agnieszka Kaczmarska, et al.
Publicado: (2021)

Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
por: Puga,Bárbara, et al.
Publicado: (2014)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz MJ, et al.
Publicado: (2020)

Manifestaciones cutáneas en donantes de sangre portadores de HTLV-1 en comparación con donantes de sangre no portadores de HTLV-1
por: García-Huidobro,Isidora, et al.
Publicado: (2014)

HTLV-I (Human T- cell lymphotropic virus), algo que decir?
por: Vásquez T,Patricia
Publicado: (2003)

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
por: Osman Cen, et al.
Publicado: (2018)

CONTENTS OF LYMPHOCYTE SUB-POPULATIONS IN THE CHILDREN WITH ACUTE LEUKEMIA AND LYMPHOMAS DEPENDENT ON INFECTIOUS COMPLICATION AND NEUTROPENIA
por: M. V. Peshikova, et al.
Publicado: (2014)

Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin.
por: Elaine F Kenny, et al.
Publicado: (2013)

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
por: Hyeok-Jae Jang, et al.
Publicado: (2021)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
por: Ana Podolski-Renić, et al.
Publicado: (2021)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Shankun Zhao, et al.
Publicado: (2021)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani C, et al.
Publicado: (2020)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Kathryn A. Skelding, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)